Details for New Drug Application (NDA): 210875
✉ Email this page to a colleague
The generic ingredient in KYNMOBI is apomorphine hydrochloride. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the apomorphine hydrochloride profile page.
Summary for 210875
Tradename: | KYNMOBI |
Applicant: | Sumitomo Pharma Am |
Ingredient: | apomorphine hydrochloride |
Patents: | 14 |
Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 210875
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | FILM;SUBLINGUAL | Strength | 10MG | ||||
Approval Date: | May 21, 2020 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jun 11, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Apr 19, 2036 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Aug 7, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? |
Expired US Patents for NDA 210875
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | ⤷ Sign Up | ⤷ Sign Up |
Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-003 | May 21, 2020 | ⤷ Sign Up | ⤷ Sign Up |
Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-002 | May 21, 2020 | ⤷ Sign Up | ⤷ Sign Up |
Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-003 | May 21, 2020 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription